Anticonvulsant Use During Pregnancy: Weighing The Risks And Benefits

Anticonvulsants are drugs used to treat epilepsy, a common neurological disease affecting around 500,000 women of childbearing age in the US alone. While most pregnancies remain uneventful, there are some risks associated with taking anticonvulsants during pregnancy, and these should be carefully considered by clinicians and patients.

Firstly, it is important to note that all antiepileptic drugs are potentially teratogenic, meaning they can cause developmental abnormalities in the fetus. However, some drugs are considered safer than others. For example, valproic acid, phenytoin, phenobarbital, and topiramate are associated with a higher risk of congenital malformations, while carbamazepine and lamotrigine present a relatively lower risk. Levetiracetam is also promising, but more studies are needed to confirm its safety.

Secondly, polytherapy (taking multiple drugs) is generally considered riskier than monotherapy (single-drug treatment). This is because the risk of major congenital malformations increases with the number of drugs taken. Therefore, it is recommended to use as few drugs as possible at the lowest effective dose.

Thirdly, drug levels should be monitored regularly during pregnancy as dosage adjustments may be necessary due to changes in the mother's pharmacokinetics. This is particularly true for drugs such as lamotrigine, levetiracetam, and oxcarbazepine.

Finally, while normal vaginal delivery is generally safe for women with epilepsy, there is an increased risk of seizures during pregnancy and delivery, which can be harmful to both the mother and the fetus. Therefore, it is crucial to have a careful management plan in place, including regular counseling and the involvement of a neurologist in the delivery process.

Anticonvulsants and their teratogenic effects

Anticonvulsants are a class of drugs used to treat epilepsy in patients. They are also used to treat other diseases such as neuropathic pain, migraines, and psychiatric disorders. The types of malformations that can result in fetuses exposed to anticonvulsants include minor anomalies, major congenital malformations, intrauterine growth retardation, cognitive dysfunction, low IQ, microcephaly, and infant mortality. The most common malformations observed secondary to in utero exposure are cardiac malformations, followed by hypospadias and facial clefts.

The risk of some anticonvulsants has been clearly established, but for newer drugs, small sample sizes and polytherapy exposures preclude a conclusive determination of their teratogenic potential. Most women with epilepsy will require anticonvulsant therapy throughout their entire pregnancy to control seizures.

The vast majority of pregnancies in women with epilepsy are uneventful, with most anticonvulsant-exposed children born free from either structural or behavioral abnormalities. However, given the in utero exposure to anticonvulsants, these children are at a greater risk of being born with birth defects. Available data strongly suggest that this increased risk for adverse outcomes observed in women with epilepsy is not a sequelae of epilepsy or seizures per se, but is instead directly due to the teratogenic effects of anticonvulsants.

While figures are quite variable based on the study design and their inherent limitations, pooled data from 26 studies revealed a major congenital malformation rate of 6.1% in offspring of women with epilepsy who were treated with anticonvulsants, 2.8% among children of women with untreated epilepsy, and 2.2% in the healthy control group. In other work, the observed frequency of major congenital malformations was 3.7% in pregnancies complicated by anticonvulsant monotherapy and 6.0% observed in anticonvulsant polytherapy.

The use of certain anticonvulsants is associated with a greater risk of specific malformations. The strongest data indicates that valproate exposure is associated with a 1–2% risk of neural tube defects, a 10- to 20-fold increase over the general population, and an increased risk of neurodevelopmental deficits.

Anticonvulsants and their impact on fetal growth

Anticonvulsants are drugs used to treat epilepsy, a neurological disorder that causes seizures. While anticonvulsants are generally safe to take during pregnancy, there are some risks associated with their use. The most common risk is an increased chance of congenital malformations, or birth defects, in the fetus. These malformations can include heart defects, cleft lip and palate, skeletal abnormalities, and neural tube defects. Other risks associated with anticonvulsant use during pregnancy include obstetrical complications, poor neonatal outcomes, and cognitive effects on the child later in life.

The risk of congenital malformations is higher for women taking valproic acid, phenytoin, phenobarbital, and topiramate. Carbamazepine and lamotrigine appear to have a lower risk of causing malformations, while levetiracetam and the newer anticonvulsants are still being studied to determine their effects.

It is recommended that women with epilepsy who are pregnant or planning to become pregnant consult with their doctor to discuss their treatment options and to ensure they are taking the safest possible drugs. Folic acid supplementation is also recommended to help reduce the risk of congenital malformations.

Anticonvulsants and their effect on cognitive development

Anticonvulsants are a group of drugs used to treat epileptic seizures. They are also used to treat bipolar disorder and borderline personality disorder. They suppress the excessive rapid firing of neurons during seizures and prevent the spread of the seizure within the brain.

Anticonvulsants can have a negative impact on cognitive performance, including a decrease in information processing speed, reaction speed, and concentration. These effects are usually reversible and fade after dose reduction or disappear after a change in substance. However, visual field defects with vigabatrin are irreversible.

The most commonly used anticonvulsants with the most favorable cognitive side-effect profile are valproic acid, carbamazepine, and phenytoin. These drugs have comparatively little effect on concentration, memory, information processing speed, or word fluency. Lamotrigine, levetiracetam, gabapentin, perampanel, lacosamide, oxcarbazepine, eslicarbazepine, and pregabalin are also associated with a minor impact on cognitive performance.

On the other hand, topiramate and zonisamide are associated with a relatively unfavorable cognitive disturbance profile. They can lead to deterioration in language skills, a slowdown in reaction speed, and a decline in working memory. These effects occur even at relatively low doses and do not seem to fade with long-term therapy.

In children, topiramate and zonisamide can also negatively affect cognitive performance, including word-finding disorders, cognitive slowdown, memory, and working memory. Valproic acid, oxcarbazepine, and carbamazepine have also been associated with deterioration in information processing speed, linguistic abilities, verbal learning, and memory processes in children.

In addition to cognitive side effects, anticonvulsants can also have psychological side effects, including depression, psychotic symptoms, and increased aggressiveness. Lamotrigine is particularly recommended for patients with depression as it has a mood-enhancing effect.

Anticonvulsant drug levels during pregnancy

Pregnancy causes dramatic changes in drug pharmacokinetics, leading to altered drug absorption, metabolism, and protein binding. This can result in decreased anticonvulsant concentrations in the body, potentially increasing the risk of seizures. Therefore, regular monitoring of drug levels is recommended during pregnancy, especially for drugs like lamotrigine, levetiracetam, and oxcarbazepine, which tend to have more pronounced clearance changes.

Additionally, it is important to note that the lowest effective dose of anticonvulsants should be prescribed to minimise potential harm to the mother and fetus. Monotherapy is generally preferred over polytherapy to reduce the risk of congenital malformations and other adverse outcomes.

The frequency of drug-level monitoring during pregnancy depends on the specific anticonvulsant being used and the patient's seizure control. For drugs with minor changes, like carbamazepine and valproic acid, less frequent monitoring may be sufficient. However, for drugs with marked and unpredictable changes, more frequent monitoring is advisable.

Furthermore, it is recommended to monitor drug levels at the beginning of each trimester and during the last month of pregnancy for women whose seizures are well-controlled. Additional monitoring may be necessary if seizures are not controlled or if side effects occur.

In summary, managing anticonvulsant drug levels during pregnancy is a complex and individualised process that requires careful consideration of the specific drug being used, the patient's seizure control, and the physiological changes occurring throughout pregnancy.

Anticonvulsants and the risk of seizures during pregnancy

Pregnant women with epilepsy are at an increased risk of suffering from pregnancy-related complications. This risk is even higher when the women are also on antiepileptic drug (AED) therapy. A pregnancy registry from India has shown that women with epilepsy are more likely to have spontaneous abortions, as well as anaemia, ovarian cysts, and fibroid uterus. Meta-analyses and population-based data from many other countries show a small but significant risk of caesarean sections, post-partum haemorrhage, and induction of labour with AED exposure. This risk should also be considered while counselling pregnant women with epilepsy. For women with epilepsy who do not take AEDs, there is a slight increase in the risk of a caesarean delivery only.

Focal seizures, including unilateral motor or non-motor seizures, or some generalised seizure types like absence and myoclonic seizures, do not have adverse effects on pregnancy or the foetus. However, they may have serious consequences if the patient sustains trauma because of them. Women with epilepsy who experience generalised tonic-clonic seizures may be at a higher risk of harming the foetus during a seizure, even though the absolute risk remains very low and the level of risk may depend on seizure frequency. It should be noted that the risk of experiencing major congenital malformations in the general population varies between 1.6% and 3.2%, and women with epilepsy who do not receive AEDs show similar rates. Hence, exposure to AEDs leads to teratogenic effects.

Newborn infants of women with epilepsy who are exposed to AEDs in utero may have low birth weight and may also be small in size for their gestational age. Studies conducted in European and North American countries have shown that such infants have higher rates of low birth weight, preterm birth, intrauterine growth retardation, and smaller head circumference at birth. These infants also have lower Apgar scores at birth.

The AEDs are among those drugs that are used as long-term medications and, unfortunately, also have substantial teratogenic effects. Apparently, teratogenicity is variable among the many different types of AEDs. Valproic acid, phenytoin, phenobarbitone, and topiramate are least favoured for use. Monotherapy is preferred over polytherapy, and the least possible dose should be used. During pregnancy, many women with epilepsy may need monthly drug-level monitoring and dose readjustments.

In summary, valproic acid has consistently shown a significantly higher risk of teratogenicity, whereas phenytoin, phenobarbitone, and topiramate pose an intermediate risk. Carbamazepine and lamotrigine present relatively lower risks of congenital malformations. The use of levetiracetam appears promising. However, bigger studies are required.

Frequently asked questions